AR036320A1 - Compuestos de benzolactama sustituidos, su uso en la fabricacion de medicamentos y las composiciones de los mismos - Google Patents
Compuestos de benzolactama sustituidos, su uso en la fabricacion de medicamentos y las composiciones de los mismosInfo
- Publication number
- AR036320A1 AR036320A1 ARP000102150A ARP000102150A AR036320A1 AR 036320 A1 AR036320 A1 AR 036320A1 AR P000102150 A ARP000102150 A AR P000102150A AR P000102150 A ARP000102150 A AR P000102150A AR 036320 A1 AR036320 A1 AR 036320A1
- Authority
- AR
- Argentina
- Prior art keywords
- disorder
- disorders
- alkyl
- syndrome
- halo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Abstract
Reivindicación 1: Un procedimiento de tratamiento de un trastorno o afección seleccionado entre distimia, trastorno depresivo mayor, depresión pediátrica, trastorno de ansiedad generalizada, trastorno obsesivo-compulsivo, trastorno de pánico, fobias tales como fobia social y agorafobia; trastorno de estrés post-traumático, trastorno de personalidad límite, dolor agudo, dolor crónico, migrana, angiogénesis, quemaduras solares, incontinencia urinaria, trastornos inflamatorios tales como artritis reumatoide, osteoartritis, psoriasis y asma; emesis, incluyendo emesis aguda, retardada y anticipada en la que el estado o el agente emético es quimioterapia, radiación, cirugía, movimiento, migrana o cualquier otro estado o agente emético; trastornos causados por Helicobacter pylory, trastornos cardiovasculares, trastornos oftálmicos, inflamación del tracto urinario, psicosis, esquizofrenia, trastorno de la conducta, trastorno de comportamiento disruptivo, trastorno bipolar, trastornos del movimiento tales como el síndrome de Tourette, síndrome de acinesia-rigidez, trastornos del movimiento asociados a la enfermedad de Parkinson, discinesia tardía y otras discinesias, trastornos cognitivos tales como demencia (incluyendo la demencia relacionada con la edad y la demencia senil de tipo Alzheimer) y trastornos de la memoria; trastornos de la alimentación tales como anorexia nerviosa y bulimia nerviosa, trastorno de hiperactividad con déficit de atención, síndrome de fatiga crónica, eyaculación precoz, síndrome premenstrual, trastorno disfórico premenstrual, dependencias y adicciones a sustancia químicas, trastornos somáticos relacionados con el estrés, neuralgia, neuropatía periférica, enfermedad de reflujo gastroesofágico, distrofia simpática refleja, tal como el síndrome de hombro/mano; trastornos de hipersensibilidad tales como hipersensibilidad a la hiedra venenosa; fibromialgia, angina, enfermedad de Reynaud, enfermedades reumáticas tales como fibrositis; eccema, rinitis, alergias, neuralgia post-herpética, cistitis, enfermedad inflamatoria del intestino, síndrome del intestino irritable, colitis, trastornos fibrosantes y del colágeno tales como escleroderma y fascioliasis eosinofílica; trastornos de la circulación sanguínea debidos a vasodilatación, y trastornos relacionados con la inducción o supresión inmune tales como lupus sistémico eritematoso, en un mamífero, incluyendo un ser humano, que comprende administrar al mamífero en necesidad de tal tratamiento una cantidad de un compuesto de fórmula química (1), en la que W es metileno, etileno, propileno, vinileno, -CH2-O-, -O-CH2, -CH2-S- ó -S-CH2-; R1, R2 y R3 son independientemente hidrógeno, alquilo C1-3, alcoxi C1-3-alquilo C1-3 o halo-alquilo C1-3, con la condición de que cuando W es metileno, ni R2 ni R3 sean hidrógeno; o uno de R2 o R3 puede ser hidroxi; X es halo, alcoxi C1-3, alquilo C1-3, halo-alcoxi C1-3 o alquenilo C1-3; Y es -NH ó -O-; Q es oxígeno o azufre y presenta un doble enlace con el carbono al que está unido, o Q es CH3 y presenta un enlace sencillo con el carbono al que está unido; y T es (2S,3S)-2-difenilmetilquinuclidin-3-ilo, (2S,3S)-2-difenilmetil-1-azanorbornan-3-ilo; o (2S,3S)-2-fenilpiperidin-3-ilo, estando el grupo fenilo de dicho (2S,3S)-2-fenilpiperidin-3-ilo opcionalmente sustituido con uno o más sustituyentes, preferiblemente de 0 a 3 sustituyentes, seleccionados independientemente entre halo, alquilo C1-6 opcionalmente sustituido con de 1 a 7 átomos de flúor, alcoxi C1-6 opcionalmente sustituido con de 1 a 7 átomos de flúor, amino, ciano, nitro, alquil C1-6-amino y di[alquil C1-6]amino; y la línea de trazos representa un doble enlace opcional; con la condición de que R1 no puede ser (alcoxi C1-3)-CH2- o halo-CH2-; o de una sal farmacéuticamente aceptable del mismo, que es eficaz en el tratamiento de tal trastorno o afección. Reivindicación 6: Una composición farmacéutica para el tratamiento de un trastorno o afección seleccionado entre distimia, trastornos depresivo mayor, depresión pediátrica, trastorno de ansiedad generalizada, trastorno obsesivo-compulsivo, trastorno de pánico, fobias tales como fobia social y agorafobia; trastorno de estrés post-traumático y trastorno de personalidad límite en un mamífero, que comprende una cantidad de un compuesto de fórmula (1), o de una sal farmacéuticamente aceptable del mismo, que es eficaz en el tratamiento de tal trastorno o afección, y un vehículo farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13285899P | 1999-05-06 | 1999-05-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036320A1 true AR036320A1 (es) | 2004-09-01 |
Family
ID=22455915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000102150A AR036320A1 (es) | 1999-05-06 | 2000-05-04 | Compuestos de benzolactama sustituidos, su uso en la fabricacion de medicamentos y las composiciones de los mismos |
Country Status (40)
| Country | Link |
|---|---|
| EP (1) | EP1175417B1 (es) |
| JP (1) | JP2002544128A (es) |
| KR (1) | KR20020015319A (es) |
| CN (1) | CN1349527A (es) |
| AP (1) | AP2001002314A0 (es) |
| AR (1) | AR036320A1 (es) |
| AT (1) | ATE257478T1 (es) |
| AU (1) | AU3572800A (es) |
| BG (1) | BG106141A (es) |
| BR (1) | BR0010673A (es) |
| CA (1) | CA2373079A1 (es) |
| CR (1) | CR6505A (es) |
| CZ (1) | CZ20013977A3 (es) |
| DE (1) | DE60007625T2 (es) |
| DK (1) | DK1175417T3 (es) |
| DZ (1) | DZ3040A1 (es) |
| EA (1) | EA200101050A1 (es) |
| EE (1) | EE200100586A (es) |
| ES (1) | ES2211520T3 (es) |
| GE (1) | GEP20043224B (es) |
| GT (1) | GT200000063A (es) |
| HK (1) | HK1046144A1 (es) |
| HR (1) | HRP20010821A2 (es) |
| HU (1) | HUP0201135A3 (es) |
| IL (1) | IL145945A0 (es) |
| IS (1) | IS6122A (es) |
| MA (1) | MA26731A1 (es) |
| MY (1) | MY133207A (es) |
| NO (1) | NO20015395L (es) |
| NZ (1) | NZ514697A (es) |
| OA (1) | OA11864A (es) |
| PA (1) | PA8494901A1 (es) |
| PE (1) | PE20010119A1 (es) |
| PL (1) | PL351919A1 (es) |
| PT (1) | PT1175417E (es) |
| TN (1) | TNSN00095A1 (es) |
| TR (1) | TR200103222T2 (es) |
| UY (1) | UY26135A1 (es) |
| WO (1) | WO2000068224A1 (es) |
| ZA (1) | ZA200109116B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0108982D0 (en) | 2001-04-10 | 2001-05-30 | Merck Sharp & Dohme | Therapeutic agents |
| JPWO2003055858A1 (ja) * | 2001-12-27 | 2005-05-12 | 東レ・ファインケミカル株式会社 | １−アルコキシカルボニル含窒素飽和複素環誘導体の製造法 |
| ATE471722T1 (de) | 2003-03-12 | 2010-07-15 | Univ Arizona State | Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen |
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| WO2009109001A1 (en) * | 2008-03-04 | 2009-09-11 | Adelaide Research & Innovation Pty Ltd | Method for preventing and/or treating a disease, condition or state associated with reduced dopaminergic neuron function |
| JP6156074B2 (ja) * | 2013-11-08 | 2017-07-05 | 住友化学株式会社 | スクシンイミド化合物及びその用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2150123C (en) * | 1992-12-10 | 2004-12-07 | Harry R. Howard | Aminomethylene substituted non-aromatic heterocycles |
| ATE199552T1 (de) * | 1995-07-07 | 2001-03-15 | Pfizer | Substituierte benzolaktamverbindungen als substanz-p-antagonisten |
| TW340842B (en) * | 1995-08-24 | 1998-09-21 | Pfizer | Substituted benzylaminopiperidine compounds |
| PT780375E (pt) * | 1995-12-21 | 2002-12-31 | Pfizer | 3-¬(benzilo substituido em 5)amino|-2-phenilpiperidinas como antagonistas da substancia p |
| TW426667B (en) * | 1997-11-19 | 2001-03-21 | Pfizer | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists |
-
2000
- 2000-04-13 OA OA1200100264A patent/OA11864A/en unknown
- 2000-04-13 CN CN00807267A patent/CN1349527A/zh active Pending
- 2000-04-13 JP JP2000616198A patent/JP2002544128A/ja active Pending
- 2000-04-13 AP APAP/P/2001/002314A patent/AP2001002314A0/en unknown
- 2000-04-13 DK DK00914335T patent/DK1175417T3/da active
- 2000-04-13 CZ CZ20013977A patent/CZ20013977A3/cs unknown
- 2000-04-13 AT AT00914335T patent/ATE257478T1/de not_active IP Right Cessation
- 2000-04-13 HU HU0201135A patent/HUP0201135A3/hu unknown
- 2000-04-13 AU AU35728/00A patent/AU3572800A/en not_active Abandoned
- 2000-04-13 KR KR1020017014110A patent/KR20020015319A/ko not_active Application Discontinuation
- 2000-04-13 BR BR0010673-9A patent/BR0010673A/pt not_active IP Right Cessation
- 2000-04-13 EP EP00914335A patent/EP1175417B1/en not_active Expired - Lifetime
- 2000-04-13 ES ES00914335T patent/ES2211520T3/es not_active Expired - Lifetime
- 2000-04-13 EE EEP200100586A patent/EE200100586A/xx unknown
- 2000-04-13 NZ NZ514697A patent/NZ514697A/en unknown
- 2000-04-13 DE DE2000607625 patent/DE60007625T2/de not_active Expired - Fee Related
- 2000-04-13 PT PT00914335T patent/PT1175417E/pt unknown
- 2000-04-13 TR TR2001/03222T patent/TR200103222T2/xx unknown
- 2000-04-13 IL IL14594500A patent/IL145945A0/xx unknown
- 2000-04-13 EA EA200101050A patent/EA200101050A1/ru unknown
- 2000-04-13 WO PCT/IB2000/000461 patent/WO2000068224A1/en not_active Application Discontinuation
- 2000-04-13 PL PL00351919A patent/PL351919A1/xx not_active Application Discontinuation
- 2000-04-13 GE GEAP20006190A patent/GEP20043224B/en unknown
- 2000-04-13 CA CA002373079A patent/CA2373079A1/en not_active Abandoned
- 2000-05-03 MA MA25966A patent/MA26731A1/fr unknown
- 2000-05-03 PA PA20008494901A patent/PA8494901A1/es unknown
- 2000-05-03 UY UY26135A patent/UY26135A1/es not_active Application Discontinuation
- 2000-05-03 TN TNTNSN00095A patent/TNSN00095A1/fr unknown
- 2000-05-03 DZ DZ000082A patent/DZ3040A1/xx active
- 2000-05-04 MY MYPI20001922A patent/MY133207A/en unknown
- 2000-05-04 AR ARP000102150A patent/AR036320A1/es unknown
- 2000-05-05 PE PE2000000418A patent/PE20010119A1/es not_active Application Discontinuation
- 2000-05-05 GT GT200000063A patent/GT200000063A/es unknown
-
2001
- 2001-10-23 IS IS6122A patent/IS6122A/is unknown
- 2001-11-05 ZA ZA200109116A patent/ZA200109116B/en unknown
- 2001-11-05 NO NO20015395A patent/NO20015395L/no not_active Application Discontinuation
- 2001-11-06 HR HR20010821A patent/HRP20010821A2/hr not_active Application Discontinuation
- 2001-11-19 CR CR6505A patent/CR6505A/es not_active Application Discontinuation
- 2001-11-23 BG BG106141A patent/BG106141A/bg unknown
-
2002
- 2002-10-29 HK HK02107807.6A patent/HK1046144A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR063331A1 (es) | Derivados de biaril eter urea y composiciones farmaceuticas | |
| AR052948A1 (es) | DERIVADOS DE ACETILENIL-PIRAZOLO-PIRIMIDINA COMO ANTAGONISTAS DE MGLUR2, METODOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU EMPLEO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES DEL SNC | |
| MX2015015893A (es) | 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen. | |
| NO20083598L (no) | Karbosykliske og heterosykliske arylsulfoner som inhibitorer av gamma-sekretase | |
| NO20083435L (no) | Formuleringer | |
| BR112012007257A2 (pt) | Uso de pelo menos um composto, processo de conservação de uma composição, composto e composições cosmética e dermatológica | |
| PE20212247A1 (es) | Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos | |
| BR122012009489B8 (pt) | processo para produzir 2-etóxi-1-{[2-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso | |
| PE20131304A1 (es) | Heteroarilos y sus usos | |
| AR036320A1 (es) | Compuestos de benzolactama sustituidos, su uso en la fabricacion de medicamentos y las composiciones de los mismos | |
| AR071314A1 (es) | Antagonistas de receptor de cgrp | |
| JP2009516759A (ja) | 耐候性エポキシ樹脂系 | |
| PE20141201A1 (es) | Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv) | |
| JP2007290980A (ja) | 含フッ素（メタ）アクリル酸エステル | |
| US10336939B2 (en) | Stabilizer compound, liquid crystal composition, and display device | |
| EA200501615A1 (ru) | (2-гидрокси-2-(4-гидрокси-3-гидроксиметилфенил)этиламино)пропилфенильные производные в качестве бета-2-агонистов | |
| MA32192B1 (fr) | Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique | |
| AR054707A1 (es) | Derivados de octahidropirrolo 3,4-c pirrol, un procedimiento para su preparacion, una composicion farmaceutica y uso del compuesto para la fabricacion de un medicamento | |
| MY194004A (en) | 4 -substituted benzoxaborole compounds and uses thereof | |
| PE20080191A1 (es) | Compuestos heterociclicos apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6 | |
| GEP20125660B (en) | Improved organic compounds | |
| NO20083955L (no) | Nye kromen-2-on-derivater og deres anvendelse som monoaminneurotransmittergjenopptaksinhibitorer | |
| AR113879A1 (es) | Derivados del tetrazolilpropilo y su uso como fungicidas | |
| AR062940A1 (es) | Compuestos para el tratamiento de desordenes metabolicos | |
| AR061433A1 (es) | Compuestos de amida del acido 3-amino-tieno (2,3,b) piridina -2-carboxilico sustituido, procesos para su preparacion y usos de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |